Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 14/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2931328 | 0.84 | PIK3CG (0.38) | PIK3CGPIK3CAPIK3CDPIK3CBDYRK1A | |
| SCHEMBL2500602 | 0.80 | CRHR1 (0.32) | — | |
| SCHEMBL2498943 | 0.67 | BRD4 (0.34) | PI4KB | |
| SCHEMBL2498882 | 0.65 | POLB (0.39) | — | |
| SCHEMBL2495462 | 0.64 | KDM4E (0.38) | — | |
| SCHEMBL544898 | 0.64 | MAPT (0.42) | — | |
| SCHEMBL2933140 | 0.63 | CRHR1 (0.38) | — | |
| SCHEMBL2495432 | 0.62 | POLB (0.40) | — | |
| SCHEMBL2493432 | 0.61 | CYP1A2 (0.37) | — | |
| SCHEMBL2929947 | 0.60 | CYP1A2 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030304-B2 | Thiazole pyrazolopyrimidines CRF1 receptor antagonists | ELI LILLY AND COMPANY (US) | 2011-10-04 | — | — | US | disclosed |
| US-20100222339-A1 | Thiazole pyrazolopyrimidines CRF1 receptor antagonists | ELI LILLY AND COMPANY | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222339-A1 | Thiazole pyrazolopyrimidines CRF1 receptor antagonists | CRHR1, CRH, CRHR2 | PIK3CG 4193/4885PIK3CA 3337/4885PIK3CD 4102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.